Monopar Therapeutics (MNPR) Operating Income (2017 - 2019)
Historic Operating Income for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.
- Monopar Therapeutics' Operating Income fell 3222.7% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.3 million, marking a year-over-year decrease of 3688.5%. This contributed to the annual value of -$4.3 million for FY2019, which is 2979.8% down from last year.
- Latest data reveals that Monopar Therapeutics reported Operating Income of -$1.2 million as of Q4 2019, which was down 3222.7% from -$759448.0 recorded in Q3 2019.
- In the past 5 years, Monopar Therapeutics' Operating Income ranged from a high of -$373839.0 in Q1 2017 and a low of -$14.9 million during Q3 2017
- For the 3-year period, Monopar Therapeutics' Operating Income averaged around -$2.0 million, with its median value being -$828354.0 (2018).
- Examining YoY changes over the last 5 years, Monopar Therapeutics' Operating Income showed a top increase of 9551.92% in 2018 and a maximum decrease of 14001.24% in 2018.
- Quarter analysis of 3 years shows Monopar Therapeutics' Operating Income stood at -$736800.0 in 2017, then fell by 25.73% to -$926358.0 in 2018, then tumbled by 32.23% to -$1.2 million in 2019.
- Its Operating Income was -$1.2 million in Q4 2019, compared to -$759448.0 in Q3 2019 and -$932109.0 in Q2 2019.